CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 165 enrolled
Drug / intervention
Deoxycholic acid injectiondrug
Likely dose
Deoxycholic acid injection 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01426373
NCT01426373Phase 3Completed

Multicenter, Open-label Study of ATX-101 (Sodium Deoxycholate Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area

Kythera Biopharmaceuticals·interventional·Posted Aug 31, 2011·Updated Jan 14, 2016

In Brief

A Phase 3 clinical trial evaluating Deoxycholic acid injection for Moderate or Severe Submental Fullness. Completed, enrolled 165 participants across 18 sites.

Detailed Summary

To evaluate the safety of deoxycholic acid subcutaneous injections in the submental area (below the chin).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 31, 2011
Enrollment StartAug 1, 2011
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.8 years ago

Interventions

Deoxycholic acid injectiondrug

Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.